This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhanel, G. G.
Right arrow Articles by Adam, H. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhanel, G. G.
Right arrow Articles by Adam, H. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2006, p. 2228-2230, Vol. 50, No. 6
0066-4804/06/$08.00+0     doi:10.1128/AAC.01620-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Mutant Prevention Concentrations of Levofloxacin Alone and in Combination with Azithromycin, Ceftazidime, Colistin (Polymyxin E), Meropenem, Piperacillin-Tazobactam, and Tobramycin against Pseudomonas aeruginosa

George G. Zhanel,1,2,3* Matthew Mayer,4 Nancy Laing,1 and Heather J. Adam1,3

Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada;,1 Departments of Medicine,2 Clinical Microbiology, Health Sciences Centre, Winnipeg, Manitoba, Canada,3 Department of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada4

Received 21 December 2005/ Returned for modification 20 February 2006/ Accepted 17 March 2006

The mutant prevention concentrations (MPCs) of levofloxacin alone and in combination with ceftazidime, colistin (polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin were established against Pseudomonas aeruginosa. Antibiotic combinations using levofloxacin with any antibiotic with individual activity against P. aeruginosa resulted in synergistic lowering (an at-least-fourfold reduction) of the isolate's MPC.

* Corresponding author. Mailing address: Clinical Microbiology, Health Sciences Centre, MS673-820 Sherbrook St., Winnipeg, Manitoba R3A 1R9, Canada. Phone: (204) 787-4902. Fax: (204) 787-4699. E-mail: ggzhanel{at}pcs.mb.ca.

Antimicrobial Agents and Chemotherapy, June 2006, p. 2228-2230, Vol. 50, No. 6
0066-4804/06/$08.00+0     doi:10.1128/AAC.01620-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»